Antibodies that detect Complement C5a can be used in several scientific applications, including Immunohistochemistry, Western Blot, ELISA, Immunocytochemistry and Functional Assay. These antibodies target Complement C5a in Human, Mouse, …

Invitrogen Anti-Complement C5a Monoclonal (D2), Catalog # MA5-43875. Tested in Western Blot (WB) applications. This antibody reacts with Human samples. Supplied as 100 µL purified antibody (1 mg/mL).

Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes.

MA1-40162 detects C5a/C5a des-Arg from human samples. MA1-40162 has been successfully used in ELISA, Immunohistochemsitry (Frozen, Paraffin), Functional Assays and Western blot applications. The MA1-40162 immunogen is the Neo-epitope on C5a.

Here, we describe the generation of a high affinity, anti-C5a antibody, MEDI7814, which neutralizes the biological effects of both C5a ligands by inhibiting C5a and C5adesArg binding to C5aR1 and C5aR2 receptors.

Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed to determine whether vilobelimab in addition to standard of care improves survival outcomes in this patient population.

C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathways of complement activation.

The finding that eculizumab, a humanised anti-C5 antibody that was approved by the US Food and Drug Administration (FDA) in 2007, can prevent complement-mediated lysis of erythrocytes and efficiently treat paroxysmal nocturnal haemoglobinuria validated complement as a …